IDEAS TO IND — YOUR PATHWAY TO DISCOVERY
ONE PARTNER
EVERY STAGE
20
Years of Genetic Innovation
10,700
Global Bioscience Partners
50,000
Mouse & Rat Models Delivered
16,500
SCI Journal Citations
250,000
SPF Animals in AAALAC-Accredited Facilities
Animal
Innovative Solutions & Trusted Products
Special Promotions & Discounts
See All Promotions
Your Partners in Preclinical Progress
Pioneering life science advancements to deliver real-world health solutions.
Our Solutions: Integrated preclinical services, including:
- ● Cell & animal model development and viral packaging.
- ● Expert-led preclinical studies.
Your Outcome: Seamlessly translating innovative research into actionable results and successful IND applications.
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Resource Library
BLOG & INSIGHTS
More Insights
Understanding Athymic Nude Mice: Foxn1 Genetics, Immunology and Oncology CDX Applications
Dive into the essential role of athymic nude mice in biomedical research. This comprehensive guide unravels the Foxn1 genetic mutation, explores their unique T-cell deficient immunological profile, and highlights their indispensable utility in validating preclinical oncology therapies through robust Cell-Derived Xenograft (CDX) models.
April 20, 2026
Read Now
UPCOMING EVENT
More
Mucins in Health & Disease 2026
Cyagen will be attending The Mucins in Health & Disease 2026 on June 15-18. Our experts will be available to discuss advanced techniques in genetically engineered mouse model generation and explore how next-generation customized animal models can support and accelerate academic research.
Schedule Meeting
WEBINAR
More
Beyond the mouse: Accelerating Drug Discovery for Obesity & T2D with HUGO-GT™
Traditional preclinical models face a 92% clinical failure rate. This webinar introduces Cyagen’s HUGO-GT™ platform to bridge this translational gap. Discover how full-length humanized models empower evaluating therapies like siRNAs for obesity and cardiovascular diseases. Attendees will review real pharmacodynamic data and explore comprehensive end-to-end CRO services.
Schedule Meeting
